Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

PRRT1 - proline-rich transmembrane protein 1

Homo sapiens

Synonyms: C6orf31, DSPD1, Dispanin subfamily D member 1, IFITMD7, NG5, ...

Valkema, R. et al., Reubi, J.C. et al., Krenning, E.P. et al., Krenning, E.P. et al., De Jong, M. et al., et al.

Reubi, Mäcke, Krenning, Esser, Krenning, Teunissen, Kooij, van Gameren, Bakker, Kwekkeboom, de Jong, Kwekkeboom, Valkema, Krenning, Valkema, Pauwels, Kvols, Kwekkeboom, Jamar, de Jong, Barone, Walrand, Kooij, Bakker, Lasher, Krenning, Krenning, Valkema, Kwekkeboom, de Herder, van Eijck, de Jong, Pauwels, Reubi, Krenning, Kwekkeboom, Valkema, Pauwels, Kvols, De Jong, De Jong, Valkema, Van Gameren, Van Boven, Bex, Van De Weyer, Burggraaf, Körner, Reubi, Krenning,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PRRT1

Patient 3 had a complete remission after PRRT with (177)Lu-DOTATATE but subsequently relapsed with many receptor-negative metastases, requiring intensive chemotherapy [1].
METHODS: Follow-up studies of 3 patients with gastroenteropancreatic neuroendocrine tumors who had been previously treated with peptide receptor radionuclide therapy (PRRT) are presented [1].
CONCLUSION: This study showed that the time course of CLR after PRRT was compatible with the pattern of sustained CLR loss in progressive chronic kidney disease [2].
Cumulative renal radiation dose, per-cycle renal radiation dose, age, hypertension, and diabetes are probable contributing factors to the rate of decline in CLR after PRRT [2].
Multi-receptor tumour targeting using the combination of bombesin and NPY(Y(1)) analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases [3].

High impact information on PRRT1

We analyzed the time course of decline in creatinine clearance (CLR) in patients during a follow-up of at least 18 mo after the start of PRRT with (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA),Tyr(3)-octreotide ((90)Y-DOTATOC) or (177)Lu-DOTA(0),Tyr(3)-octreotate ((177)Lu-DOTATATE) [2].
For PRRT of CCK-B receptor-positive tumors, such as medullary thyroid carcinoma, radiolabeled minigastrin analogues currently are being successfully applied [4].
Simultaneous RIAs of a series of patient plasmas using either of the two radioligands with antiserum NG5/5 produced indistinguishable discrimination between samples (r = 0.984) [5].
Some use octreotide as the peptide for peptide receptor radionuclide therapy (PRRT) [6].
Dose-limiting factors for PRRT are bone marrow and/or kidney dose [6].

Chemical compound and disease context of PRRT1

At the present time, PRRT is performed primarily with somatostatin receptor- and cholecystokinin-2 (CCK2)-receptor-expressing neuroendocrine tumors with radiolabeled octreotide analogs or with radiolabeled CCK2-selective analogs [7].

Anatomical context of PRRT1

Multireceptor tumor targeting using the combination of bombesin and NPY(Y(1)) analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases [4].

Analytical, diagnostic and therapeutic context of PRRT1

This review describes the candidate tumors eligible for such radiotherapy on the basis of their peptide receptor content and discusses factors in PRRT eligibility [7].
In peptide receptor radionuclide therapy (PRRT) using somatostatin analogs labeled with beta-emitters, the radiosensitive kidney is the dose-limiting organ, because of high uptake and retention of the radionuclides after glomerular filtration [8].

References

Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. Krenning, E.P., Valkema, R., Kwekkeboom, D.J., de Herder, W.W., van Eijck, C.H., de Jong, M., Pauwels, S., Reubi, J.C. J. Nucl. Med. (2005) [Pubmed]
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Valkema, R., Pauwels, S.A., Kvols, L.K., Kwekkeboom, D.J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P.P., Bakker, W.H., Lasher, J., Krenning, E.P. J. Nucl. Med. (2005) [Pubmed]
Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. de Jong, M., Kwekkeboom, D., Valkema, R., Krenning, E.P. Eur. J. Nucl. Med. Mol. Imaging (2003) [Pubmed]
Peptide receptor radionuclide therapy. Krenning, E.P., Kwekkeboom, D.J., Valkema, R., Pauwels, S., Kvols, L.K., De Jong, M. Ann. N. Y. Acad. Sci. (2004) [Pubmed]
Radioimmunoassay for the middle region of human parathyroid hormone: comparison of two radioiodinated synthetic peptides. Sharp, M.E., Marx, S.J. Clin. Chim. Acta (1985) [Pubmed]
Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [ (177)Lu-DOTA (0),Tyr (3)]octreotide: which peptide is preferable for PRRT? Esser, J.P., Krenning, E.P., Teunissen, J.J., Kooij, P.P., van Gameren, A.L., Bakker, W.H., Kwekkeboom, D.J. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
Candidates for peptide receptor radiotherapy today and in the future. Reubi, J.C., Mäcke, H.R., Krenning, E.P. J. Nucl. Med. (2005) [Pubmed]
Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. De Jong, M., Valkema, R., Van Gameren, A., Van Boven, H., Bex, A., Van De Weyer, E.P., Burggraaf, J.D., Körner, M., Reubi, J.C., Krenning, E.P. J. Nucl. Med. (2004) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.